AOD-9604 research guide for Rai. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
For anyone in Rai searching for AOD-9604, the foundational reality is that this compound is available only through an online research supply market. This concentration of supply in online vendors is ultimately a quality advantage — top vendors differentiate through analytical documentation in ways no local retailer can match. Vendors worth sourcing from openly share batch-matched Certificates of Analysis containing HPLC chromatograms, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the exact batch you are purchasing. What follows is a practical research guide built specifically around AOD-9604, covering everything a Rai researcher needs before placing a first order.
AOD-9604 Mechanisms Explained
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Rai comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
AOD-9604 Purchasing Guide
Quality AOD-9604 sourcing begins with a straightforward question: does this vendor publish batch-specific COAs proactively? Suppliers that publish proactively are signalling genuine quality commitment. The HPLC chromatogram is the most important document in the COA: it should show a dominant main peak representing AOD-9604, with negligible secondary peaks representing impurities — purity should be at or above 98%. Positive vendor signals beyond COA quality: established track record of at least two years, customer service that can discuss analytical methods, and cold chain packaging that protects product integrity. Price is an unreliable primary filter for AOD-9604 quality — research-grade synthesis and testing has real costs that do not compress without quality compromise, so the lowest-priced options almost always involve trade-offs.
Order AOD-9604 — ships to Rai
COA-verified · International tracking · Research grade
AOD-9604 is supplied strictly for research applications and is not approved for human consumption by the FDA or comparable health authorities — all information here is educational. Proper handling of AOD-9604 requires strict sterile technique during reconstitution — swabbed septum with alcohol prep pad, new needle for each draw, clean preparation area — and temperature control throughout the entire workflow. The primary quality-related safety risk in AOD-9604 research is bacterial endotoxin from low-quality material — a verified endotoxin panel in the batch COA is the direct mitigation for this hazard. Researchers combining AOD-9604 with other compounds should examine published studies for potential interaction data before running stacked compound experiments.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
